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1. Introduction 
The inexorable trend towards ageing population and 
increasingly higher prevalence and mortality associated with 
Alzheimer's disease (AD) makes more urgent than ever the 
development of effective treatments that address the underlying 
disease mechanisms. Overproduction and aggregation of β-
amyloid peptide (Aβ),1,2 hyperphosphorylation and aggregation 
of tau protein,3 and oxidative stress4,5 have been separately 
reported as the earliest causative factors of AD, giving rise to 
alternative pathological hypotheses and the derived single-target 
therapeutic approaches. Indeed, apart from the prevailing 
amyloid cascade hypothesis of AD, which posits Aβ as the main 
culprit of the disease,1,2 in the past years particular emphasis has 
been placed on oxidative stress as a factor preceding Aβ and tau 
pathologies and precipitating the pathogenesis of AD.4–7 This has 
prompted the clinical study of dietary antioxidants for preventing 
or delaying the progression of AD.6,7 Disappointingly, like in the 
case of Aβ-directed drug candidates the clinical testing of 
antioxidants has met with very limited success.6,7 Even though a 
low bioavailability of antioxidants has been suggested as a 
possible reason of failure in clinical trials, their lack of clinical 
efficacy has been also ascribed to the fact that oxidative stress 
may not be the sole cause of AD,8,9 as it would be also the case of 
Aβ and tau pathologies.10 Conversely, all these processes likely 
display a similarly important role in a complex pathological 
network, making their simultaneous modulation necessary, i.e. a 
multitarget therapeutic intervention, in the pursuit of effective 
anti-Alzheimer treatments.8,9  
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Multitarget compounds are increasingly being pursued for the effective treatment of complex 
diseases. Herein, we describe the design and synthesis of a novel class of shogaol–huprine 
hybrids, purported to hit several key targets involved in Alzheimer’s disease. The hybrids have 
been tested in vitro for their inhibitory activity against human acetylcholinesterase and 
butyrylcholinesterase and antioxidant activity (ABTS.+, DPPH and Folin-Ciocalteu assays), and 
in intact Escherichia coli cells for their Aβ42 and tau anti-aggregating activity. Also, their brain 
penetration has been assessed (PAMPA-BBB assay). Even though the hybrids are not as potent 
AChE inhibitors or antioxidant agents as the parent huprine Y and [4]-shogaol, respectively,
they still exhibit very potent anticholinesterase and antioxidant activities and are much more 
potent Aβ42 and tau anti-aggregating agents than the parent compounds. Overall, the shogaol–
huprine hybrids emerge as interesting brain permeable multitarget anti-Alzheimer leads. 
2009 Elsevier Ltd. All rights reserved.
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 Figure 1. Structures of the natural antioxidant [6]-shogaol and the AChE 
inhibitor huprine Y. 
 
In the past years intensive research efforts have been made for 
developing multitarget anti-Alzheimer hybrid compounds that hit 
several of these processes, prominently Aβ aggregation and 
oxidative stress, as well as the cholinergic deficit responsible for 
the cognitive decline of AD patients through inhibition of 
acetylcholinesterase (AChE).8 Usually, the starting point for the 
design of such compounds is the structure of a known AChE 
inhibitor, which is linked to an antioxidant pharmacophoric 
moiety,11–18 e.g. phenolics and polyphenolics derived fragments. 
The resulting hybrid compounds are in some cases endowed with 
Aβ antiaggregating activity, likely due to the presence of flat 
aromatic systems in their structures. Of note, in line with the 
increasingly accepted notion that the aggregation of 
amyloidogenic proteins, such as Aβ and tau, might share 
common mechanisms and might be tackled by the same drugs,19 
we have recently reported that several AChE inhibitor (huprine or 
tacrine)-based hybrid compounds display a dual Aβ and tau 
antiaggregating action, hereby broadening their multitarget 
profile.20,21 
[6]-Shogaol (1, Fig. 1) is one of the major bioactive 
constituents of ginger (Zingiber officinale), a plant used 
worldwide as a spice and also widely used in the Chinese 
traditional medicine. It has been recently reported that [6]-
shogaol exhibits potent antioxidant and anti-inflammatory 
activities, its enone moiety being essential for these activities.22,23 
Interestingly, [6]-shogaol enhances antioxidant defense 
mechanisms both in cell cultures and in mice24 and counteracts 
the hydrogen peroxide-induced increase of reactive oxygen 
species (ROS) in HT22 cells, an in vitro model of hippocampal 
cholinergic neurons.25 
Herein, we describe the design, synthesis, and 
pharmacological evaluation of a short series of multitarget anti-
Alzheimer hybrid compounds that combine a unit of the highly 
potent AChE inhibitor huprine Y (2, Fig. 1) with the 4-hydroxy-
3-methoxyphenylpentenone moiety of shogaols. The 
pharmacological characterization of these compounds includes 
the evaluation of their inhibitory activities towards human AChE 
and butyrylcholinesterase (BChE), Aβ42 and tau aggregation, 
and their antioxidant activity, measured through the ABTS.+, 
DPPH and Folin-Ciocalteu methods. Also, the brain permeability 
of the novel compounds has been assessed by the widely used 
parallel artificial membrane permeability assay (PAMPA-BBB). 
2. Results and discussion 
2.1. Binding mode within human AChE: Molecular 
modelling studies 
The antioxidant activity of shogaols seems to reside in the α,β-
unsaturated ketone, apart from the phenolic ring, irrespective of 
the alkyl chain length.22 Thus, for the design of the novel 
shogaol–huprine hybrids, the selection of the optimal length of 
the tether, which was to link the phenolic ring of the shogaol unit 
and the huprine moiety, was carried out by investigating the 
binding mode of the hybrids within AChE. To this end, docking 
calculations were performed using three models of the human 
AChE (hAChE), which differ in the orientation of Trp286 in the 
peripheral anionic site (PAS) (see section 4.3). Thus, in each 
model Trp286 was arranged to reflect one of the three major 
conformations found upon inspection of the available X-ray 
crystallographic structures.26  
A series of hybrids differing in the number of methylene units 
present between the huprine and shogaol units were docked in the 
hAChE models. On the basis of docking calculations, a 
preferential binding to the hAChE model in which Trp286 retains 
the orientation found in the AChE–propidium complex (PDB ID 
1N5R) in conjunction with a chain of eight carbon atoms for the 
tether in the shogaol–huprine hybrids (i.e. compound 5 in 
Scheme 1) was found. This chain length should enable the 
simultaneous binding to both the catalytic anionic site (CAS) and 
PAS of hAChE, which are at the bottom and at the entrance of 
the enzyme catalytic gorge, separated by a distance of 
approximately 14 Å.27 Thus, the huprine unit was located in the 
pocket defined by residues Trp86 and Tyr337 in the CAS, 
forming a direct hydrogen-bond contact with the carbonyl 
oxygen of His447. In fact, the binding mode reproduces the main 
features of the arrangement found for (–)-huprine X, the 9-ethyl-
analogue of huprine Y, bound to the Torpedo californica AChE 
(PDB entry 1E66),28 and for (–)-huprine W, which bears a 
hydroxyethyl group at position 9, bound to the human enzyme 
(PDB entry 4BDT).29 On the other hand, the phenolic ring 
stacked against Trp286 in the PAS (Fig. 2). Nevertheless, the 
flexibility conferred by the polymethylene linker in hybrid 5 
leads to different arrangements of the tether in the midgorge 
region, because the carbonyl group present in the tether is 
capable of forming hydrogen bonds with either Tyr124 or Tyr72, 
as shown in Fig. 2A. 
As the introduction of aromatic rings in the linker of dual 
binding site AChE inhibitors has been studied with the main aims 
of imposing rigidity30 and providing additional interactions with 
aromatic midgorge residues, thereby increasing the inhibitory 
potency,31 we also explored the potential effect of introducing a 
benzene ring conjugated with the α,β-unsaturated ketone (i.e. 
compound 9 in Scheme 2). This structural change did not alter 
the ability of the compound to stack against Trp86 and Trp286 in 
the CAS and PAS, respectively (Fig. 2B). In contrast to 5, 
however, most of the docked poses clustered into a single 
orientation characterized by a hydrogen bond of the carbonyl unit 
and Tyr72. Overall, the introduction of the benzene ring 
conjugated with the enone does not appear to be detrimental for 
the binding mode of the compound within AChE, while it might 
be valuable to improve the pharmacological profile of the 
shogoal–huprine hybrids by targeting the amyloid (Aβ42 and tau) 
aggregation besides cholinesterase and radical scavenging 
activities. 
2.2. Synthesis of the shogaol–huprine hybrids 
First, we envisioned the synthesis of hybrid 5 (Scheme 1), 
bearing the 1-(4-hydroxy-3-methoxyphenyl)-4-alken-3-one 
moiety of shogaols, with the aliphatic chain attached to the 
exocyclic amino group of huprine Y. 
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Figure 2. Structural detail of the binding mode of the shogaol–huprine 
hybrids 5 (A) and 9 (B) to hAChE. 
 
 
Scheme 1. Synthesis of the shogaol–huprine hybrid 5. 
 
The synthesis of hybrid 5 involved the initial alkylation of 
racemic huprine Y with 5-bromo-1-pentene, which proceeded in 
30% yield (Scheme 1). Subsequent cross metathesis reaction 
between the alkenylhuprine 3 and the known enone 4 ([4]-
shogaol)32 using the Hoveyda-Grubbs second generation catalyst 
in the presence of p-benzoquinone, afforded hybrid 5 in 15% 
yield, after two consecutive tedious silica gel column 
chromatography purifications. The observation in the 1H NMR 
spectrum of 5 of a coupling constant of 15.6 Hz in the signals of 
the two enone olefin protons was clearly indicative of the E 
configuration of its carbon-carbon double bond. 
 
 
Scheme 2. Synthesis of the shogaol–huprine hybrids 9 and 10. 
 
For the synthesis of hybrid 9 we used as starting material the 
nitrile 6,20 which was quantitatively reduced with DIBAL-H to 
the corresponding aldehyde, 7 (Scheme 2). Next, we carried out a 
Mannich-type condensation of aldehyde 7 with zingerone, 8, at 
80 ºC in a closed vessel, promoted by dimethylammonium 
dimethyl carbamate (DIMCARB) through formation of the 
iminium cation intermediate.32 After three consecutive silica gel 
column chromatography purifications of the resulting reaction 
crude, the desired hybrid 9 was obtained in 13% isolated yield. 
Of note, byproduct 10, bearing a dimethylaminomethyl 
substituent at position 3 of the phenolic ring, was also isolated in 
15% yield. The structure of 10 was unambiguously assigned on 
the basis of bidimensional NMR experiments (COSY 1H/1H and 
COSY 1H/13C (gHSQC or gHMBC sequences)) and HRMS. 
The structural similarity of compound 10 with hybrid 9 and 
the fact that the presence of an aliphatic amino group in 10, 
protonatable at physiological pH, might enhance the interaction 
of the phenolic moiety with the AChE PAS aromatic residues 
(mainly Trp286) prompted us to subject also compound 10 to 
biological evaluation. 
2.3. Acetylcholinesterase inhibitory activity 
The inhibitory activity of the racemic shogaol–huprine hybrids 
5, 9, and 10 against recombinant hAChE was evaluated by the 
method of Ellman et al.,33 and compared with that of the parent 
racemic huprine Y, 2, and [4]-shogaol, 4, under the same assay 
conditions.  
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 Table 1 
Inhibitory activities of shogaol–huprine hybrids and reference compounds against AChE, BChE, Aβ42 and tau aggregation, 
antioxidant capacity, and BBB predicted permeabilities 
Compd hAChE 
IC50 (nM)a 
hBChE  
IC50 (nM)a 
ABTS.+ 
(trolox 
equiv.)b 
DPPH 
(trolox 
equiv.)b 
Total 
phenolics 
(mg gallic 
acid equiv / 
g sample)b 
Aβ42 aggregation  
(% inhib. at 10 µM)c 
Tau aggregation  
(% inhib. at 10 µM)c 
Pe (10–6 cm s–6)d 
(Prediction) 
5 6.7 ± 0.1 982 ± 190 7.6 ± 0.6 6.6 ± 0.5 29.8 ± 2.6 39.3 ± 2.8 35.2 ± 2.3 11.7 ± 0.4 (CNS+) 
9 18.3 ± 2.0 742 ± 74 10.5 ± 0.6 8.8 ± 0.7 50.0 ± 2.4 70.6 ± 4.3 51.0 ± 1.9 6.5 ± 0.8 (CNS+) 
10 21.1 ± 1.9 181 ± 27 11.8 ± 0.5 2.8 ± 0.1 68.8 ± 4.3 53.9 ± 4.4 40.1 ± 2.4 8.4 ± 1.3 (CNS+) 
2 0.7 ± 0.03e 175 ± 6e 2.6 ± 0.2 1.0 ± 0.01 10.2 ± 1.3 8.9 ± 1.3 7.6 ± 3.4 21.9 ± 1.2 (CNS+) 
4 f g 26.2 ± 0.2 12.2 ± 0.2 384 ± 25 10.5 ± 0.8 9.2 ± 0.7 14.7 ± 0.5 (CNS+) 
Gallic 
acid 
  18.6 ± 0.1 10.3 ± 0.04 1033 ± 25    
a
 IC50 inhibitory concentration (nM) of human recombinant AChE and human 
serum BChE. IC50 values are expressed as mean ± standard error of the mean 
(SEM) of at least four experiments, each performed in duplicate. 
b
 Antioxidant capacity measured through ABTS+, DPPH, or total 
polyphenols. Values are expressed as mean ± SEM of three experiments. 
c
 % Inhibition of Aβ42 and tau protein aggregation at 10 µM in intact E. coli 
cells. Values are expressed as mean ± SEM of four independent experiments. 
d
 Permeability values from the PAMPA-BBB assay. Values are expressed as 
the mean ± SD of three independent experiments. 
e
 Data from ref. 34. 
f
 28% inhibition at 10 µM. 
g
 6% inhibition at 10 µM. 
 
The shogaol–huprine hybrids are very potent inhibitors of 
hAChE, with IC50 values in the low nanomolar range (7–21 nM), 
being much more potent than the parent [4]-shogaol (28% 
inhibition at 10 µM) but less potent than huprine Y (Table 1). 
The most potent hybrid was compound 5, which is indeed the 
most genuine shogaol–huprine hybrid, as it formally results from 
merging the structure of [4]-shogaol and huprine Y. Hybrid 5 is 
however only 3-fold more potent than analogues 9 and 10, 
bearing a benzene ring conjugated with the shogaol enone group. 
The presence of an additional basic nitrogen atom at the phenolic 
ring in hybrid 10 has no influence on the hAChE inhibitory 
activity, this compound being equipotent to hybrid 9 (Table 1). 
2.4. Butyrylcholinesterase inhibitory activity 
Like AChE, BChE hydrolyzes the neurotransmitter 
acetylcholine in brain. This role of BChE is especially important 
when the amount of AChE in CNS decreases in the advanced 
stages of AD. For this reason, inhibition of BChE is an 
increasingly pursued activity in the search for anti-Alzheimer 
agents.35 In this light, the BChE inhibitory activity of the 
shogaol–huprine hybrids against human serum BChE (hBChE) 
was evaluated by the method of Ellman et al..33 
The parent huprine Y exhibits a potent hBChE inhibitory 
activity, even though it is much more potent against hAChE 
(250-fold). Conversely, the parent [4]-shogaol is essentially 
inactive for hBChE inhibition (6% inhibition at 10 µM). Like 
huprine Y, the shogaol–huprine hybrids turned out to be potent 
inhibitors of hBChE (submicromolar IC50 values) and selective 
towards hAChE (selectivity factors of 9–147) (Table 1). The 
structural features leading to higher hBChE inhibitory activity 
were just the opposite as for hAChE inhibition, i.e. the hybrids 
bearing the benzene ring conjugated with the shogaol enone 
moiety were the most potent, and, in this case, the presence of the 
amino group at the phenolic ring had a significant influence on 
this activity, hybrid 10 being 5- and 4-fold more potent hBChE 
inhibitor than 5, and 9, respectively, and equipotent to huprine Y. 
2.5. Antioxidant activity 
To evaluate the putative beneficial effects of the shogaol–
huprine hybrids against oxidative stress, their antioxidant 
capacity (AC) and that of the parent huprine Y and [4]-shogaol 
was assessed using an ABTS.+ radical decolorization assay and 
the DPPH assay. For many years the Folin-Ciocalteu (F-C) assay 
has been used as a measure of total phenolics (TP) in natural 
products. However, because the basic mechanism is an 
oxidation/reduction reaction, it can be considered another method 
for the assessment of AC.36 Consequently, the shogaol–huprine 
hybrids were also subjected to this assay. Gallic acid, a naturally 
occurring phenolic acid, and trolox, a water-soluble analogue of 
vitamin E, with well-established antioxidant activities were also 
evaluated as positive standards. The results were calculated as 
trolox equivalents (µmol trolox / µmol tested compound) for the 
ABTS.+ and DPPH assays and as mg of gallic acid equivalents 
(GAE)/g sample for the F-C assay. 
The shogaol–huprine hybrids exhibited a potent antioxidant 
activity in the ABTS.+ and DPPH assays (3–12 trolox equiv., 
Table 1), as well as in the TP assay. The order of antioxidant 
potencies was 10 > 9 > 5, with the sole exception of the DPPH 
assay, where hybrid 10 was surprisingly less potent than their 
analogues, albeit still being 3-fold more potent than trolox. As 
compared with the reference compounds, the hybrids were less 
potent antioxidant agents than the parent [4]-shogaol, 4, and 
gallic acid, but more potent than huprine Y, 2, the latter strikingly 
displaying a remarkable potency, especially in the ABTS.+ and 
DPPH assays (1–2.6 trolox equiv.). The antioxidant activity 
found in this work for huprine Y might account for the 
neuroprotective effect recently found in another class of huprine-
based heterodimeric compounds against the hydrogen peroxide 
insult in neuroblastoma SHSY5Y cells.37 
Thus, even though the shogaol phenolic ring and the enone 
group and, to a minor extent, the huprine moiety of these hybrids 
must impart antioxidant activity, the presence in the linker of the 
benzene ring conjugated with the shogaol enone group as well as 
the dimethylaminomethyl group at the shogaol phenolic ring of 
10 seemed to be beneficial for antioxidant activity. 
Overall, the potent antioxidant activity of the shogaol–huprine 
hybrids constitutes a very valuable complement to their potent 
anticholinesterase inhibitory activities in the context of a 
multitarget anti-Alzheimer treatment. 
2.6. Aβ42 and tau anti-aggregating activity 
Together with oxidative stress and cholinergic dysfunction, 
amyloid and tau pathologies are regarded as pivotal pathogenic 
factors in AD, and therefore, of prime importance as targets of 
multifunctional drugs.  
Some classes of AChE inhibitors, especially dual binding site 
inhibitors, are often endowed with Aβ anti-aggregating 
properties,38 which arise either from blockade of the AChE 
peripheral anionic site (PAS) (blockade of AChE-induced Aβ 
aggregation)39–41 or from a direct interaction with Aβ (blockade 
of spontaneous Aβ aggregation), in the latter case likely due to 
the presence of aromatic planar moieties in the inhibitors. 
Overexpression of amyloid-prone proteins in bacteria usually 
leads to the formation of insoluble inclusion bodies (IBs), which 
display the main amyloid-like features. Taking advantage of the 
fact that amyloid aggregation can be followed in vivo in bacteria, 
we have recently developed a methodology that allows the fast, 
easy, and inexpensive screening of inhibitors of the spontaneous 
aggregation of potentially any amyloidogenic protein that can be 
overexpressed in Escherichia coli cells.21 When these proteins 
aggregate inside E. coli they usually form IBs that can be stained 
with Thioflavin-S (Th-S). The extent of aggregation of those 
proteins can be monitored measuring the variations of the 
fluorescence of Th-S. In brief, overexpression of recombinant 
amyloid-prone proteins entails an increase of Th-S fluorescence 
compared to bacteria that do not express the protein. When 
bacteria overexpressing recombinant amyloid-prone proteins are 
grown in the presence of amyloid aggregation inhibitors the Th-S 
fluorescence is clearly reduced. Because the Th-S fluorescence is 
directly proportional to the amyloid amount in bacteria, the anti-
aggregating capacity of each inhibitor can be easily determined. 
The Th-S binding to IBs can be assessed either by steady-state 
fluorescence or by visualization of IBs using optical microscopy 
under UV-light. In the latter case, the fluorescence is determined 
using image processing programs. Of note, we have shown that 
the results obtained in the screening of inhibitors of Aβ42 
aggregation correlate well with the Aβ anti-aggregating activity 
values found in vitro using synthetic Aβ42,21 this methodology 
thus emerging as a economic surrogate of the classical in vitro 
tests. 
The Aβ42 and tau anti-aggregating activity of the novel 
shogaol–huprine hybrids were determined using this 
methodology (Table 1 and Figs. 3 and 4). In line with previous 
findings with other structural families, similar potencies for each 
hybrid against Aβ42 and tau aggregation and the same order of 
potencies for both activities among the three hybrids were found, 
which supports the existence of common mechanisms behind the 
aggregation of different amyloidogenic proteins and the 
likelihood of common treatments against different amyloidogenic 
diseases.19 In this particular class of compounds, the Aβ42 and 
tau anti-aggregating activities were in the ranges 39–71% and 
35–51%, respectively, using a 10 µM concentration of the 
hybrids, they being clearly more potent than the parent huprine Y 
and [4]-shogaol, 4 (around 10% inhibition at 10 µM, Table 1). 
The order of potencies among the hybrids for both activities 
was 9 > 10 > 5. As expected, the presence of the additional 
benzene ring in the linker of hybrids 9 and 10 relative to 5 led to 
higher Aβ42 and tau anti-aggregating activities. On the other 
hand, the presence of the dimethylaminomethyl group in the 
phenolic ring of 10 was rather detrimental for these activities. 
 
Figure 3. Optical fluorescence microscopy images under UV light of 
bacterial cells overexpressing Aβ42 peptide stained with Th-S. A) Induced 
control; B) not induced control; and  in the presence of anti-aggregating 
compounds: C) huprine Y; D) hybrid 9; E) Hybrid 10; F) Hybrid 5. Scale bar 
corresponds to 5 µm. 
 
Figure 4. Optical fluorescence microscopy images under UV light of 
bacterial cells overexpressing tau protein stained with Th-S. A) Induced 
control; B) not induced control; and in the presence of anti-aggregating 
compounds: C) huprine Y; D) hybrid 9; E) Hybrid 10; F) Hybrid 5.. Scale bar 
corresponds to 5 µm. 
 
The Aβ42 and tau anti-aggregating potencies of the hybrids 
seem to be independent from their AChE inhibitory activities. 
One the one hand, the anti-aggregating potencies of the hybrids 
and the parent huprine Y do not correlate with their AChE 
inhibitory potencies. On the other hand, the Aβ42 and tau anti-
aggregating potencies are determined in the absence of AChE. 
Even though the precise mechanisms involved in the Aβ42 and 
tau anti-aggregating activity of the shogaol–huprine hybrids are 
not known, as previously mentioned and in agreement with the 
beneficial effect of the additional benzene ring in hybrids 9 and 
10, the presence of several aromatic moeties with extended π-
conjugated systems seems to play an important role.42 
 Overall, hybrids 9 and 10 emerge as moderately potent Aβ42 
and tau anti-aggregating agents, with IC50 values that must be in 
the low micromolar range. 
 
 
2.7. Brain penetration 
A good permeation through the blood–brain barrier (BBB) is a 
necessary condition for CNS drugs. Previous results from in 
vitro, ex vivo, and in vivo studies have shown that huprine Y and 
several classes of huprine-based hybrid compounds can readily 
cross the BBB, leading to central effects.20,34,43,44 Conversely, 
phenolic antioxidants usually have low bioavailabilities and 
inherent difficulties to cross the BBB,6,9,45 thereby making it 
imperative the assessment of the ability of the shogaol–huprine 
hybrids to enter the brain. 
Brain permeation of these hybrids was determined through an 
in vitro test that uses an artificial membrane model, namely the 
well-established PAMPA-BBB method.46 The in vitro 
permeability (Pe) of the shogaol–huprine hybrids, the parent 
compounds huprine Y and [4]-shogaol, and 14 commercial drugs, 
the later used for assay validation (Table 2, Experimental), 
through a lipid extract of porcine brain was determined. 
Comparison of the experimental and reported permeability values 
of commercial drugs provided a good linear correlation: Pe (exp) 
= 1.5605 Pe (lit) – 1.0507 (R2 = 0.9308). Using this equation and 
the limits established by Di et al. for BBB permeation,46 it was 
established that compounds with Pe (10−6 cm s−1) > 5.2 would 
have high BBB permeation (CNS+) and compounds with Pe (10−6 
cm s
−1) < 2.1 would have low BBB permeation (CNS−). 
The three shogaol–huprine hybrids, like the parent huprine Y 
and [4]-shogaol, were predicted to be able to cross the BBB, as 
their Pe values were above the threshold for high BBB 
permeation (Table 1), which should enable them to reach their 
multiple CNS targets. Notwithstanding the apparent brain 
permeability of the shogaol–huprine hybrids, it would remain to 
be determined whether other pharmacokinetic properties are so 
favourable, especially taking into account the known phase II 
metabolic liability of polyphenolic compounds.47,48 
3. Conclusion 
We have synthesized the shogaol–huprine hybrids 5, 9, and 10 
through two-step synthetic sequences starting from the known 
huprine Y or its N-(4-cyanobenzyl) derivative 6, which involve 
as the key step a cross metathesis or a Mannich-type 
condensation reaction. In agreement with the design strategy, 
these hybrids turned out to be potent inhibitors of human 
cholinesterases (both hAChE and hBChE) and potent antioxidant 
agents, even though this hybridization strategy led to slightly 
decreased hAChE inhibitory activity relative to the parent 
huprine Y, as we have found in other classes of huprine-based 
multitarget agents,20,34,49 or to decreased antioxidant activity 
relative to the parent [4]-shogaol. 
 The presence of the additional aromatic ring in the linker of 
hybrids 9 and 10, which leads to increased antioxidant activity, 
seemingly enhances their interaction with Aβ42 and tau protein, 
leading to potent Aβ42 and tau anti-aggregating activities. 
Shogaol–huprine hybrids emerge as interesting leads in the 
pursuit of effective treatments of AD, insofar as they might be 
able to readily cross the BBB and modulate several key 
pathological targets or events of AD such as oxidative stress, 
cholinergic dysfunction and Aβ and tau pathologies. 
4. Experimental 
4.1. Molecular modelling 
Molecular modelling was performed using the X-ray 
crystallographic structure of hAChE (PDB ID: 4BDT).29 The 
structure was refined by removal of N-acetyl-D-glucosamine and 
sulphate anions and addition of missing hydrogen atoms. Three 
disulfide bridges were defined between Cys residues 257–272, 
409–529, and 69–96, respectively. The enzyme was modelled in 
its physiological active form with neutral His447 and 
deprotonated Glu334, which together with Ser203 form the 
catalytic triad. The ionization state for the rest of ionizable 
residues was assessed with PROPKA3.50 Accordingly, the 
standard ionization state at neutral pH was considered but for 
residues Glu285, Glu450 and Glu452, which were protonated. 
Since Trp286 can adopt three main conformations in the 
peripheral binding site, three models were built up by re-
orienting the side chain of Trp286 as found in the X-ray 
structures of the AChE complexes with propidium, bis(7)-tacrine 
and syn-TZ2PA6 (PDB ID: 1N5R, 2CKM and 1Q83, 
respectively).26 These models were energy minimized using the 
AMBER force field.51 
Docking of AChE inhibitors was performed using the rDock 
program.52 A cavity of radius 17 Å, centered on the structure of a 
superligand containing huprine X, donepezil and propidium (as 
found in the X-ray structures 1E66, 1EVE and 1N5R) was used 
to define the docking volume. Since huprine X and propidium are 
bound to the catalytic and the peripheral binding sites, and 
donepezil is aligned along the gorge, this definition guarantees 
the exploration of the binding mode along the whole volume 
accessible for binding. Conformational flexibility around 
rotatable bonds of the ligand was allowed. Docking calculations 
were performed separately for the three hAChE models (see 
above). Conformational adjustments of other residues in the 
binding site were accounted for indirectly by rescaling (by a 
factor of 0.9) the van der Waals volume of atoms. Additionally, a 
pharmacophoric restraint between the protonated nitrogen in the 
huprine moiety of the inhibitor and the carbonyl oxygen of 
His447 in the CAS of the enzyme was applied. Each compound 
was subjected to 100 docking runs and the poses were sorted 
according to its docking score. The top 50 best scored poses were 
clustered and further analysed by visual inspection. 
4.2. Chemistry 
Melting points were determined in open capillary tubes with a 
MFB 595010M Gallenkamp melting point apparatus. 300 MHz 
1H, 400 MHz 1H / 100.6 MHz 13C and 500 MHz 1H / 125.8 MHz 
13C NMR spectra were recorded on Varian Gemini 300, Varian 
Mercury 400, and Varian Inova 500 spectrometers, respectively, 
at the Centres Científics i Tecnològics of the University of 
Barcelona (CCiTUB). The chemical shifts are reported in ppm (δ 
scale) and coupling constants are reported in Hertz (Hz). 
Assignments given for the NMR spectra of hybrid 10 have been 
carried out on the basis of DEPT, COSY 1H/1H (standard 
procedures), and COSY 1H/13C (gHSQC or gHMBC sequences) 
experiments. IR spectra were run on a Perkin-Elmer Spectrum 
RX I spectrophotometer, using KBr pellets or the Attenuated 
Total Reflectance (ATR) technique. Absorption values are 
expressed as wave-numbers (cm−1); only significant absorption 
bands are given. Column chromatography was performed on 
silica gel 60 AC.C (35−70 µM, SDS, ref 2000027). Thin-layer 
chromatography was performed with aluminum-backed sheets 
with silica gel 60 F254 (Merck, ref 1.05554), and spots were 
visualized with UV light and 1% aqueous solution of KMnO4. 
High resolution mass spectra of all of the new compounds were 
performed at the CCiTUB with a LC/MSD-TOF Agilent 
Technologies spectrometer. The analytical samples of all of the 
compounds that were subjected to pharmacological evaluation 
were dried at 65 ºC / 2 Torr at least for 2 days (standard 
conditions). 
4.2 .1 .  3-Chloro-6 ,7 ,10 ,11 -te trahydro -9-methyl -12-
(4-pentenyl )-7 ,11-methanocyclooc ta[b ]quinol ine 
(3)  
A suspension of racemic huprine Y, 2 (1.50 g, 5.27 mmol) and 
finely powdered NaOH (420 mg, 10.5 mmol), and 4 Å molecular 
sieves in anhydrous DMSO (15 mL) was stirred, heating every 
10 min approximately with a heat gun for 1 h and at rt one 
additional hour, and then treated dropwise with 5-bromo-1-
pentene (0.69 mL, 868 mg, 5.82 mmol). The reaction mixture 
was stirred at rt overnight, diluted with 5N NaOH (250 mL) and 
extracted with EtOAc (3×300 mL). The combined organic 
extracts were washed with H2O (3×200 mL), dried over 
anhydrous Na2SO4, and evaporated at reduced pressure to give a 
yellow oil (1.03 g), which was purified by column 
chromatography (35–70 µm silica gel, CH2Cl2/50% aq. NH4OH 
100:0.2 mixture). The alkene 3 (562 mg, 30% yield) and starting 
2 (338 mg) were consecutively isolated; Rf(3) 0.63 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05).  
A solution of 3 (106 mg, 0.30 mmol) in CH2Cl2 (10 mL) was 
filtered through a 0.2 µm PTFE filter and treated with a 0.75 N 
methanolic solution of HCl (1.2 mL, 0.90 mmol). The resulting 
solution was evaporated at reduced pressure and the solid was 
washed with pentane (3×2 mL) to give, after drying under 
standard conditions, 3·HCl (110 mg) as a yellowish solid: mp 
128–129 °C (CH2Cl2 / MeOH 89:11); IR (KBr) ν 3500–2500 
(max at 3226, 3111, 3049, 3004, 2925, 2854, 2717, N–H, +N–H, 
C–H st), 1717, 1699, 1684, 1669, 1629, 1582, 1569, 1560 (Ar–
C–C and Ar–C–N st) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.57 
(s, 3H, 9-CH3), 1.91–2.02 (complex signal, 4H, 13-Hsyn, 10-Hendo 
and 2’-H2), 2.08 (dm, J 12.8 Hz, 1H, 13-Hanti), 2.10 (dt, J, J’  7.2 
Hz, 3’-H2), 2.56 (dd, J 17.6 Hz, J’ 4.8 Hz, 1H, 10-Hexo), 2.76 (m, 
1H, 7-H), 2.89 (d, J 17.6 Hz, 1H, 6-Hendo), 3.21 (dd, J 17.6 Hz, J’ 
5.2 Hz, 1H, 6-Hexo), 3.48 (m, 1H, 11-H), 3.99 (dt, J, J’ 6.8 Hz, 
2H, 1’-H2), 4.86 (s, NH and +NH), 5.00 (ddt, J 10.4 Hz, J’, J” 1.6 
Hz, 1H, 5’-Ha), 5.04 (ddt, J 17.2 Hz, J’, J” 1.6 Hz, 1H, 5’-Hb), 
5.57 (br d, J 4.8 Hz, 1H, 8-H), 5.86 (ddt, J 17.2 Hz, J’ 10.4, J” 
6.8 Hz, 1H, 4’-H), 7.52 (d, J 9.6 Hz, 1H, 2-H), 7.80 (s, 1H, 4-H), 
8.36 (d, J 9.6 Hz, 1H, 1-H); 13C NMR (100.6 MHz, CD3OD) δ 
23.5 (CH3, 9-CH3), 27.2 (CH, C11), 27.8 (CH, C7), 29.3 (CH2, 
C13), 30.5 (CH2), 31.9 (CH2) (C2’ and C3’), 36.0 (CH2, C6), 
36.2 (CH2, C10), 50.9 (CH2, C1’), 115.6 (C, C12a), 116.3 (CH2, 
C5’), 117.9 (C, C11a), 119.1 (CH, C4), 125.1 (CH, C8), 126.6 
(CH, C2), 129.4 (CH, C1), 134.5 (C, C9), 138.4 (CH, C4’), 140.1 
(C, C3), 140.9 (C, C4a), 151.3 (C, C5a), 156.9 (C, C12); HRMS 
(ESI), calcd for [C22H2535ClN2 + H+] 353.1779, found 353.1777. 
4.2 .2 .  8-[ (3 -Chloro-6 ,7 ,10 ,11 -te trahydro-9 -methyl -
7 ,11-methanocyc loocta [b ]quinol in-12-y l)amino]-1 -
(4-hydroxy-3 -methoxyphenyl)oct -4-en-3 -one (5 )  
A mixture of a solution of alkene 3 (725 mg, 2.05 mmol) in 
anhydrous CH2Cl2 (28 mL), enone 4 (765 mg, 3.08 mmol), p-
benzoquinone (21 mg, 0.19 mmol) and Hoveyda-Grubbs 2nd 
generation catalyst (65 mg, 0.10 mmol) was stirred under reflux 
for 3 days. The resulting mixture was directly purified through 
two consecutive column chromatographies (35–70 µm silica gel, 
CH2Cl2/MeOH/50% aq. NH4OH and hexane/EtOAc mixtures, 
gradient elution), to afford hybrid 5 (158 mg, 15% yield). The 
analytical sample of 5 (30 mg) was obtained by preparative thin 
layer chromatography of an aliquot amount of the product (100 
mg), followed by washing with pentane (3×3 mL); Rf 0.71 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.15); mp 69–71 ºC; IR 
(ATR) ν 3352 (O–H, N–H st), 1666, 1660, 1632, 1603, 1572, 
1556, 1514 (C=O, Ar–C–C, Ar–C–N st) cm–1; 1H NMR (400 
MHz, CDCl3) δ 1.51 (s, 3H, 9”-CH3), 1.78 (br d, J 16.4 Hz, 1H, 
10”-Hendo), 1.86 (tt, J, J’ 6.8 Hz, 2H, 7-H2), 1.92 (dm, J 12.0 Hz, 
1H, 13”-Hsyn), 2.05 (dm, J 12.0 Hz, 1H, 13”-Hanti), 2.33 (dtd, J, J’ 
6.8 Hz, J” 1.6 Hz, 2H, 6-H2), 2.54 (dm, J 16.4 Hz, 1H, 10”-Hexo), 
2.74 (m, 1H, 7”-H), 2.78–2.89 (complex signal, 4H, 1-H2, 2-H2), 
3.01 (br d, J 17.6 Hz, 1H, 6”-Hendo), 3.15 (dd, J 17.6 Hz, J’ 5.2 
Hz, 1H, 6”-Hexo), 3.29 (m, 1H, 11”-H), 3.46 (m, 2H, 8-H2), 3.86 
(s, 3H, 3’-OCH3), 5.54 (br d, J 4.4 Hz, 1H, 8”-H), 6.11 (dt, J 15.6 
Hz, J’ 1.6 Hz, 1H, 4-H), 6.67 (dd, J 8.0 Hz, J’ 2.0 Hz, 1H, 6’-H), 
6.70 (d, J 2.0 Hz, 1H, 2’-H), 6.80 (dt, J 15.6 Hz, J’ 6.8 Hz, 1H, 
5-H), 6.82 (d, J 8.0 Hz, 1H, 5’-H), 7.27 (dd, J 8.8 Hz, J’ 2.0 Hz, 
1H, 2”-H), 7.87 (d, J 8.8 Hz, 1H, 1”-H), 7.89 (d, J 2.0 Hz, 1H, 
4”-H); 13C NMR (100.6 MHz, CD3OD) δ 23.6 (CH3), 28.4 (CH), 
29.5 (CH), 30.1 (CH2), 30.7 (CH2), 30.8 (CH2), 31.0 (CH2), 38.0 
(CH2), 40.4 (CH2), 42.8 (CH2), 50.1 (CH2), 56.4 (CH3), 113.2 
(CH), 116.1 (CH), 119.9 (C), 121.7 (CH), 122.2 (C), 125.1 (CH), 
126.1 (CH), 126.6 (CH), 127.4 (CH), 131.5 (C), 131.9 (CH), 
133.6 (C), 133.9 (C), 135.7 (C), 145.8 (C), 148.5 (CH), 148.9 
(C), 152.8 (C), 159.4 (C), 202.4 (C); HRMS (ESI), calcd for 
[C32H3535ClN2O3 + H +] 531.2409, found 531.2405. 
4.2 .3 .  4-{ [ (3 -Chloro -6 ,7 ,10 ,11 -te trahydro-9 -
methyl -7 ,11-methanocycloocta[b ]quinol in-12-
yl )amino]methy l}benza ldehyde (7)  
A solution of nitrile 6 (337 mg, 0.84 mmol) in anhydrous 
toluene (14 mL) was cooled to 0 ºC and treated dropwise with 
DIBAL-H (1.2 M solution in toluene, 1.05 mL, 1.26 mmol). The 
reaction mixture was stirred at 0 ºC overnight, and treated 
successively with 2 N HCl (5 mL) and 10 N NaOH (30 mL) at 0 
ºC. The resulting mixture was extracted with CH2Cl2 (3×50 mL) 
and the combined organic extracts were washed with water (2×50 
mL), dried over anhydrous Na2SO4 and evaporated at reduced 
pressure to give crude aldehyde 7 (354 mg, quantitative), which 
was used in the next step without further purification; Rf 0.27 
(CH2Cl2/MeOH 99:1); 1H NMR (300 MHz, CDCl3) δ 1.50 (s, 3H, 
9’-CH3), 1.72 (br d, J 17.4 Hz, 1H, 10”-Hendo), 1.85 (dm, J 12.6 
Hz, 1H, 13’-Hsyn), 1.98 (dm, J 12.6 Hz, 1H, 13’-Hanti), 2.46 (dm, 
J 17.4 Hz, 1H, 10’-Hexo), 2.73 (m, 1H, 7’-H), 3.02 (ddd, J 17.7 
Hz, J’, J” 2.1 Hz, 1H, 6’-Hendo), 3.16 (dd, J 17.7 Hz, J’ 5.7 Hz, 
1H, 6’-Hexo), superimposed 3.14–3.20 (m, 1H, 11’-H), 4.23 (t, J 
6.9 Hz, 1H, NH-CH2-Ph), 4.68 (d, J 6.9 Hz, 2H, NH-CH2-Ph), 
5.53 (m, 1H, 8’-H), 7.15–7.30 (complex signal), 7.56 (d, J 8.1 
Hz), and 7.80–8.00 (complex signal) [7H, 2(6)-H, 3(5)-H, 1’-H, 
2’-H, 4’-H], 10.05 (s, 1H, Ph-CHO); HRMS (ESI), calcd for 
[C25H2335ClN2O + H +] 403.1571, found 403.1578. 
4.2 .4 .  1-{4-{ [(3 -Chloro -6 ,7 ,10 ,11-te trahydro-9 -
methyl -7 ,11-methanocycloocta[b ]quinol in-12-
yl )amino]methy l}phenyl} -5- (4 -hydroxy-3-
methoxyphenyl )pent -1-en-3 -one  (9 )  and 1 -{4-{ [ (3 -
chloro -6 ,7 ,10 ,11- te trahydro-9-methyl -7 ,11-
methanocyclooc ta[b ]quinol in-12-
yl )amino]methy l}phenyl} -5- [3 -
(d imethylamino)methyl -4 -hydroxy-5-
methoxyphenyl ]pent -1-en-3 -one  (10 )  
A mixture of a solution of ketone 8 (86 mg, 0.44 mmol) in 
dimethylammonium dimethyl carbamate (DIMCARB, 29 µL, 30 
mg, 0.23 mmol) and a solution of aldehyde 7 (178 mg, 0.44 
mmol) in CH2Cl2 (1.2 mL) was heated in a closed vessel at 80 ºC 
overnight and the mixture was evaporated at reduced pressure. 
After three consecutive purifications by column chromatography 
(35–70 µm silica gel, two with CH2Cl2/MeOH/50% aq. NH4OH 
100:0:0.2 to 99.9:0.1:0.2 and one with EtOAc as the eluents), the 
desired hybrid 9 (32 mg, 13% yield) and the byproduct 10 (43 
mg, 15% isolated yield) were isolated; Rf(9) 0.73 
(CH2Cl2/MeOH/50% aq. NH4OH 90:10:0.15); Rf(10) 0.68 
(CH2Cl2/MeOH/50% aq. NH4OH 90:10:0.15). 
The analytical samples of 9·HCl (5 mg) and 10·2HCl (27 mg) 
were obtained by treatment of the free bases with a 0.53 N 
methanolic solution of HCl (0.25 mL, 0.13 mmol for 9; 0.45 mL, 
0.24 mmol for 10), evaporation, recrystallization from 
MeOH/EtOAc/hexane 1:2:0.5 (1.75 mL), and washing with 
pentane (3×3 mL). 
9·HCl: mp 140–142 ºC (MeOH/EtOAc/hexane 1:2:0.5); IR 
(ATR) ν 3500–2500 (max. at 3215, 2923, O–H, N–H, +N–H, C–
H st), 1631, 1600, 1582, 1563, 1513 (C=O, Ar–C–C, Ar–C–N st) 
cm
–1
. 
9 (free base): 1H NMR (400 MHz, CDCl3) δ 1.48 (s, 3H, 9”-
CH3), 1.70 (br d, J 16.8 Hz, 1H, 10”-Hendo), 1.83 (dm, J 12.4 Hz, 
1H, 13”-Hsyn), 1.97 (dm, J 12.4 Hz, 1H, 13”-Hanti), 2.43 (br dd, J 
16.8 Hz, J’ 3.6 Hz, 1H, 10”-Hexo), 2.72 (br s, 1H, 7”-H), 2.92–
3.01 (complex signal, 4H, 4-H2, 5-H2), 3.02 (br d, J 17.2 Hz, 1H, 
6”-Hendo), 3.148 (dd, J 17.2 Hz, J’ 5.2 Hz, 1H, 6”-Hexo), 
superimposed 3.154 (m, 1H, 11”-H), 3.87 (s, 3H, 3’-OCH3), 4.23 
(br signal, 2H, OH, NH), 4.63 (br s, 2H, NH-CH2-Ph), 5.52 (br d, 
J 4.4 Hz, 1H, 8”-H), 6.72 (dd, J 8.0 Hz, J’ 2.0 Hz, 1H, 6’-H), 
6.74 (d, J 16.4 Hz, 1H, 2-H), 6.75 (d, J 2.0 Hz, 1H, 2’-H), 6.84 
(d, J 8.0 Hz, 1H, 5’-H), 7.27 (dd, J 8.8 Hz, J’ 2.0 Hz, 1H, 2”-H), 
7.38 (dm, J 8.0 Hz, 2H, p-phenylene-Hmeta), 7.54 (d, J 8.0 Hz, 
2H, p-phenylene-Hortho), 7.55 (d, J 16.4 Hz, 1H, 1-H), 7.92 (d, J 
8.8 Hz, 1H, 1”-H), 7.93 (d, J 2.0 Hz, 1H, 4”-H); 13C NMR (100.6 
MHz, CDCl3) significant signals δ 23.3 (CH3), 27.5 (CH), 28.1 
(CH), 28.9 (CH2), 29.7 (CH2), 37.1 (CH2), 39.9 (CH2), 42.9 
(CH2), 54.0 (CH2), 55.9 (CH3), 111.2 (CH), 114.4 (CH), 119.1 
(C), 120.8 (CH), 122.5 (C), 124.8 (CH), 125.0 (CH), 125.5 (CH), 
126.4 (CH), 127.7 (CH), 128.0 (2CH), 128.8 (2CH), 141.7 (C), 
141.9 (CH), 144.0 (C), 146.4 (C), 148.4 (C), 149.7 (C), 158.9 
(C), 199.4 (C); HRMS (ESI), calcd for [C36H3535ClN2O3 + H +] 
579.2409, found 579.2406. 
10·2HCl: mp 163–167 ºC (MeOH/EtOAc/hexane 1:2:0.5); IR 
(ATR) ν 3500–2500 (max. at 3215, 3039, 2922, 2702, O–H, N–
H, +N–H, C–H st), 1630, 1600, 1582, 1566, 1504 (C=O, Ar–C–C, 
Ar–C–N st) cm–1; 1H NMR (500 MHz, CD3OD) δ 1.61 (s, 3H, 
9”-CH3), superimposed 1.95–2.00 (m, 1H, 13”-Hsyn), 1.98 (br d, J 
17.0 Hz, 1H, 10”-Hendo), 2.10 (dm, J 11.0 Hz, 1H, 13”-Hanti), 2.56 
(dm, J 17.0 Hz, 1H, 10”-Hexo), 2.80 (m, 1H, 7”-H), 2.84 [s, 6H, 
3’-CH2-N(CH3)2], 2.91 (d, J 18.0 Hz, 1H, 6”-Hendo), 2.93 (t, J 7.0 
Hz, 2H, 5-H2), 3.07 (t, J 7.0 Hz, 2H, 4-H2), 3.25 (dd, J 18.0 Hz, 
J’ 5.5 Hz, 1H, 6”-Hexo), 3.51 (m, 1H, 11”-H), 3.89 (s, 3H, 5’-
OCH3), 4.27 [s, 2H, 3’-CH2-N(CH3)2], 4.85 (s, OH, NH, and 
+NH), 5.23 (s, 2H, NH-CH2-Ph), 5.61 (dm, J 4.5 Hz, 1H, 8”-H), 
6.82 (s, 1H, 2’-H), 6.88 (d, J 16.0 Hz, 1H, 2-H), 6.99 (s, 1H, 6’-
H), 7.39 (dd, J 9.0 Hz, J’ 2.0 Hz, 1H, 2”-H), 7.48 (br d, J 8.0 Hz, 
2H, p-phenylene-Hmeta), 7.65 (d, J 16.0 Hz, 1H, 1-H), 7.71 (br d, 
J 8.0 Hz, 2H, p-phenylene-Hortho), 7.77 (d, J 2.0 Hz, 1H, 4”-H), 
8.20 (d, J 9.0 Hz, 1H, 1”-H); 13C NMR (125.8 MHz, CD3OD) δ 
23.5 (CH3, 9”-CH3), 27.6 (CH, C11”), 27.9 (CH, C7”), 29.3 
(CH2, C13”), 30.7 (CH2, C5), 36.1 (CH2, C6”), 36.3 (CH2, C10”), 
43.2 (CH2, C4), 43.3 [2CH3, 3’-CH2-N(CH3)2], 52.1 (CH2, NH-
CH2-Ph), 56.6 (CH3, 5’-OCH3), 57.9 [CH2, 3’-CH2-N(CH3)2], 
114.7 (CH, C6’), 115.7 (C, C12a”), 117.1 (C, C3’), 118.4 (C, 
C11a”), 119.3 (CH, C4”), 124.3 (CH, C2’), 125.2 (CH, C8”), 
126.8 (CH, C2”), 127.6 (CH, C2), 128.4 (2CH, p-phenylene-
Cmeta), 129.2 (CH, C1”), 130.3 (2CH, p-phenylene-Cortho), 134.3 
(C, C1’), 134.7 (C, C9”), 135.8 (C, p-phenylene-Cipso), 140.4 (C, 
C3”), 140.9 (C, C4a”), 141.4 (C, p-phenylene-Cpara), 143.7 (CH, 
C1), 145.4 (C, C4’), 149.1 (C, C5’), 152.0 (C, C5a”), 157.4 (C, 
C12”), 202.0 (C, C3); HRMS (ESI), calcd for [C39H4235ClN3O3 + 
H +] 636.2987, found 636.2975. 
4.3. Biological profiling 
4 .3 .1 .  AChE and BChE inhibi tory act iv i t i es  
Human recombinant AChE (Sigma-Aldrich) and human 
serum BChE (Sigma-Aldrich) inhibitory activities were evaluated 
spectrophotometrically by the method of Ellman et al..33 The 
reactions took place in a final volume of 300 µL of 0.1 M 
phosphate-buffered solution pH 8.0, containing hAChE or 
hBChE (0.02 u/mL) and 333 µM 5,5'-dithiobis(2-nitrobenzoic) 
acid (DTNB; Sigma-Aldrich) solution used to produce the yellow 
anion of 5-thio-2-nitrobenzoic acid. Inhibition curves were 
performed in duplicate using at least 10 increasing concentrations 
of inhibitors and preincubated for 20 min at 37 ºC before adding 
the substrate.49 One duplicate sample without inhibitor was 
always present to yield 100% of AChE or BChE activities. Then 
substrates, acetylthiocholine iodide (450 µM; Sigma-Aldrich) or 
butyrylthiocholine iodide (300 µM; Sigma-Aldrich), were added 
and the reaction was developed for 5 min at 37 ºC. Colour 
production was measured at 414 nm using a labsystems 
Multiskan spectrophotometer.  
Data from concentration–inhibition experiments of the 
inhibitors were calculated by non-linear regression analysis, 
using the GraphPad Prism program package (GraphPad 
Software; San Diego, USA), which gave estimates of the IC50 
(concentration of drug producing 50% of enzyme activity 
inhibition). Results are expressed as mean ± S.E.M. of at least 4 
experiments performed in duplicate. 
4.3 .2 .  Antioxidant  ac t i v i t y  
4 .3 .2 .1 .  Standards  and reagents  
Folin-Ciocalteu (F-C) reagent, sodium carbonate, ABTS 
(2,2’azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), trolox 
((±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid), 
caffeic acid, chlorogenic acid, gallic acid, quercetin, ascorbic 
acid, and manganese dioxide were purchased from Sigma Aldrich 
(Madrid, Spain), and DPPH (2,2-diphenyl-1-picrylhydrazyl) from 
Extrasynthèse (Genay, France). MeOH and EtOH were obtained 
from Scharlau (Barcelona, Spain), HOAc from Panreac 
(Barcelona, Spain), anhydrous sodium acetate (2 M) from Merck 
(Darmstadt, Germany), and ultrapure water (Milli-Q) from 
Millipore (Bedford, USA). 
4.3 .2 .2 .  Sample pretreatment  
Samples (1 mg) were weighed and homogenized with EtOH 
(1 mL). The homogenate was sonicated for 5 min and filtered 
through a 0.45 µm polytetrafluoroethylene (PTFE) filter from 
Waters (Milford, USA) into a vial. 
4.3 .2 .3 .  Antioxidant  capaci ty :  ABTS . +  assay  
The antioxidant capacity (AC) was first measured using an 
ABTS.+ radical decolorization assay.53 1 mM Trolox (standard 
antioxidant) was prepared in MeOH. Working standards were 
obtained by diluting 1 mM trolox with MeOH. Solutions of 
known trolox concentration were used for calibration. An ABTS.+ 
radical cation was prepared by passing a 5 mM aqueous stock 
solution of ABTS (in MeOH) through manganese dioxide 
powder. Excess manganese dioxide was filtered through a 0.45 
µm PTFE filter. Then, 245 µL of ABTS.+ solution were added to 
5 µL of trolox or to samples and the solutions were stirred for 30 
s. The homogenate was shaken vigorously and kept in darkness 
for 1 h. Absorption of the samples was measured on a UV/VIS 
Thermo Multiskan Spectrum spectrophotometer at 734 nm and 
MeOH blanks were run in each assay. Results were expressed as 
trolox equivalents (µmol trolox / µmol tested compound). 
Analyses were carried out in triplicate. 
4.3 .2 .4 .  Antioxidant  capaci ty :  DPPH assay  
The antioxidant capacity (AC) was also determined through 
the evaluation of the free radical-scavenging effect on the DPPH 
radical.53 Solutions of known trolox concentration were used for 
calibration. 5 µL of samples or trolox were mixed with 250 µL of 
methanolic DPPH (0.025 g L–1). The homogenate was shaken 
vigorously and kept in darkness for 30 min. Absorption of the 
samples was measured on the spectrophotometer at 515 nm. 
Results were expressed as trolox equivalents (µmol trolox / µmol 
tested compound). Analyses were carried out in triplicate. 
4.3 .2 .5 .  Analys is  o f  to ta l  polyphenols  
For the TP assay, each sample was analyzed three times; 20 
µL of the samples were mixed with 188 µL of Milli-Q water in a 
thermo microtiter 96-well plate (nuncTM, Roskilde, Denmark), 
and 12 µL of F-C reagent and 30 µL of sodium carbonate (200 
g/L) were added following a described procedure.54 The mixtures 
were incubated for 1 h at room temperature in the dark. After the 
reaction period, 50 µL of Milli-Q water was added and the 
absorbance was measured at 765 nm in a UV/Vis Thermo 
Multiskan Spectrum spectrophotometer (Vantaa, Finland). 
Results were expressed as mg of gallic acid equivalents (GAE)/g 
sample. 
4.3 .3 .  Aβ42 and tau ant iaggregat ing ac t i v i t ies  in  
Escherich ia  col i  cel l s  
4 .3 .3 .1 .  Cloning  and overexpress ion of  Aβ42 
pept ide  
E. coli BL21 (DE3) competent cells were transformed with 
the pET28a vector (Novagen, Inc., Madison, WI, USA) carrying 
the DNA sequence of Aβ42. Because of the addition of the 
initiation codon ATG in front of both genes, the overexpressed 
peptide contains an additional methionine residue at its N 
terminus. For overnight culture preparation, lysogeny broth (LB) 
medium (10 mL) containing kanamycin (50 µg·mL–1) were 
inoculated with a colony of BL21 (DE3) bearing the plasmid to 
be expressed at 37 °C. After overnight growth, the OD600 was 
usually 2–2.5. For expression of Aβ42 peptide, overnight culture 
(20 µL) was transferred into Eppendorf tubes of 1.5 mL 
containing LB medium (960 µL) with kanamycin (50 µg·mL–1), 
isopropyl 1-thio-β-D-galactopyranoside (IPTG, 1 mM), 10 µM 
solution of each hybrid or reference compound in DMSO (10 
µL), and 25 µM solution of Th-S in water (10 µL). The samples 
were grown for 24 h at 37 °C and 1400 rpm using a 
Thermomixer (Eppendorf, Hamburg, Germany). In the negative 
control (without drug) the same amount of DMSO was added in 
the sample. 
4.3 .3 .2 .  Cloning  and overexpress ion of  tau 
protein  
E. coli BL21 (DE3) competent cells were transformed with 
pTARA containing the RNA-polymerase gene of T7 phage 
(T7RP) under the control of the promoter pBAD. E. coli BL21 
(DE3) with pTARA competent cells were transformed with 
pRKT42 vector encoding four repeats of tau protein in two 
inserts. For overnight culture preparation, M9 medium (10 mL) 
containing glucose (0.5%), ampicillin (50 µg·mL–1), and 
chloramphenicol (12.5 µg·mL–1) were inoculated with a colony 
of BL21 (DE3) bearing the plasmids to be expressed at 37 °C. 
After overnight growth, the OD600 was usually 2–2.5. For 
expression of tau protein, overnight culture (20 µL) was 
transferred into Eppendorf tubes of 1.5 mL containing M9 
medium (970 µL) with arabinose (0.25%), glucose (0.5%), 
ampicillin (50 µg·mL–1) and chloramphenicol (12.5 µg·mL–1), 10 
µM solution of each hybrid or reference compound in DMSO (10 
µL), and 25 µM solution of Th-S in water (10 µL). The samples 
were grown for 24 h at 37 °C and 1400 rpm using a 
Thermomixer (Eppendorf, Hamburg, Germany). In the negative 
control (without drug) the same amount of DMSO was added in 
the sample. 
4.3 .3 .3 .  Th-S s teady-s ta te  f luorescence  
Th-S (T1892) and other chemical reagents were purchased 
from Sigma (St. Louis, MO). Th-S stock solution (2.5 mM) was 
prepared in double-distilled water purified through a Milli-Q 
system (Millipore, USA). Fluorescent spectral scans of Th-S 
were analyzed using an Aminco Bowman Series 2 luminescence 
spectrophotometer (Aminco-Bowman AB2, SLM Aminco, 
Rochester, NY, USA). Excitation and emission slit widths of 4 
nm were used. Finally, the fluorescence emission at 455 nm, 
when exciting at 375 nm, was recorded. In order to normalize the 
Th-S fluorescence as a function of the bacterial concentration, 
OD600 was obtained using a Shimadzu UV-2401 PC UV/Vis 
spectrophotometer (Shimadzu, Japan). The final fluorescence 
data were obtained considering as 100% the Th-S fluorescence of 
the bacterial cells expressing the peptide or protein in the absence 
of drug and 0% the Th-S fluorescence of the bacterial cells non-
expressing the peptide or protein. Final data are the average of 
ten independent experiments. 
4.3 .3 .4 .  Optical  f luorescence microscopy  
Bacterial cells overexpressing Aβ42 peptide and tau protein 
were incubated for 1 h in the presence of 125 µM Th-S. Th-S was 
removed by centrifugation and the cells were re-suspended in 
PBS and placed on a microscope slide. Th-S fluorescence was 
detected under UV light using a GFP filter with an excitation 
filter BP480/40 and an emission filter BP527/30 using a Leitz 
DMIRB microscope. The fluorescence enhancement as a 
consequence of Th-S binding to IBs has been determined using 
Quantity One 1-D Analysis Software Version 4.6.9 (Bio-Rad, 
Hercules, CA, USA) as image processing program. 
4.3 .4 .  Determinat ion  of  bra in permeabi l i t y:  
PAMPA-BBB assay  
The in vitro permeability (Pe) of the novel hybrids and 
fourteen known drugs through lipid extract of porcine brain 
membrane was determined by using a parallel artificial 
membrane permeation assay,46 using a mixture PBS:EtOH 70:30. 
Assay validation was made by comparison of the experimental Pe 
values of the known drugs with their reported values, which 
showed a good correlation: Pe (exp) = 1.5605 Pe (lit) – 1.0507 
(R2 = 0.9308). From this equation and the limits established by Di 
et al. for BBB permeation,46 three ranges of permeability were 
established: compounds of high BBB permeation  (CNS+): Pe 
(10−6 cm s−1) > 5.19; compounds of low BBB permeation (CNS–
): Pe (10−6 cm s−1) < 2.07; and  compounds of uncertain BBB 
permeation (CNS+/–): 5.19 > Pe (10−6 cm s−1) > 2.07. 
Table 2 
Reported and experimental permeability values (Pe 10–6 cm s–
1) of 14 commercial drugs used for the PAMPA-BBB assay 
validation 
Compound  Literature valuea Experimental valueb  
Cimetidine 0.0 0.70 ± 0.03 
Lomefloxacin 1.1 0.75 ± 0.02 
Norfloxacin 0.1 0.90 ± 0.02 
Ofloxacin 0.8 0.98 ± 0.02 
Hydrocortisone 1.9 1.40 ± 0.05 
Piroxicam 2.5 1.83 ± 0.19 
Clonidine 5.3 6.50 ± 0.05 
Corticosterone 5.1 6.70 ± 0.10 
Imipramine 13 12.3 ± 0.10 
Promazine 8.8 13.8 ± 0.30 
Progesterone 9.3 16.8 ± 0.30 
Desipramine 12 17.8 ± 0.10 
Testosterone 17 24.3 ± 0.46 
Verapamil 16 25.2 ± 1.07 
a
 Taken from ref. 46. 
b
 Values are expressed as the mean ± SD of three independent experiments. 
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